Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of Attr Amyloidosis With Cardiomyopathy
Alnylam向歐洲藥品管理局提交了Vutrisiran用於治療伴有心肌病的ATTR澱粉樣變性的監管申請
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of Attr Amyloidosis With Cardiomyopathy
Alnylam向歐洲藥品管理局提交了Vutrisiran用於治療伴有心肌病的ATTR澱粉樣變性的監管申請
譯文內容由第三人軟體翻譯。